SoaS score
6.3/10
Priced ahead of it
The story
Sakar's case leans on oncology exports converting through marketing authorizations and tech transfers; the latest call was guarded, and the price already banks the ramp.
SoaS score
6.3/10
Priced ahead of it
API-integrated pharma maker of oncology and general formulations; sells via CDMO, own-brand exports, and dossier licensing.
The story
Sakar's case leans on oncology exports converting through marketing authorizations and tech transfers; the latest call was guarded, and the price already banks the ramp.
The good
The bad
Growth Score
Solid
Revenue growth · 2Y view
Bear
15-20%
Base
25-30%
Bull
32-37%
10 more live